Journal of Yeungnam Medical Science

Case report

Hematology
Severe congenital neutropenia mimicking chronic idiopathic neutropenia: a case report: Juhyung Kim, Soyoon Hwang, Narae Hwang, Yeonji Lee, Hee Jeong Cho, Joon Ho Moon, Sang Kyun Sohn, Dong Won Baek; J Yeungnam Med Sci. 2023;40(3):283-288. Published online July 28, 2022; DOI: https://doi.org/10.12701/jyms.2022.00353

7,747 View
152 Download
1 Web of Science
3 Crossref

Severe chronic neutropenia is classified as severe congenital, cyclic, autoimmune, or idiopathic. However, there is a lot of uncertainty regarding the diagnosis of severe congenital neutropenia (SCN) and chronic idiopathic neutropenia, and this uncertainty affects further evaluations and treatments. A 20-year-old man presented with fever and knee abrasions after a bicycle accident. On admission, his initial absolute neutrophil count (ANC) was 30/µL. He had no medical history of persistent severe neutropenia with periodic oscillation of ANC. Although his fever resolved after appropriate antibiotic therapy, ANC remained at 80/µL. Bone marrow (BM) aspiration and biopsy were performed, and a BM smear showed myeloid maturation arrest. Moreover, genetic mutation test results showed a heterozygous missense variant in exon 4 of the neutrophil elastase ELANE: c597+1G>C (pV190-F199del). The patient was diagnosed with SCN. After discharge, we routinely checked his ANC level and monitored any signs of infection with minimum use of granulocyte colony-stimulating factor (G-CSF), considering its potential risk of leukemic transformation. Considering that SCN can be fatal, timely diagnosis and appropriate management with G-CSF are essential. We report the case of a patient with SCN caused by ELANE mutation who had atypical clinical manifestations. For a more accurate diagnosis and treatment of severe chronic neutropenia, further studies are needed to elucidate the various clinical features of ELANE.

Citations

Citations to this article as recorded by

Zahnmedizinische Betreuung seltener Erkrankungen: Fallberichte zu hereditärer sensorischer und autonomer Neuropathie sowie zu schwerer chronischer Neutropenie
Wieland Elger
Kinder- und Jugendmedizin.2025; 25(03): 162. CrossRef
Severe Congenital Neutropenia in a Newborn Caused by a Novel Mutation in the ELANE Gene—First Report From North Macedonia and a Literature Review: A Case Report
Nikolina Zdraveska, Teodora Trajkovska, Aleksandra Jovanovska, Arjeta Hasani, Mica Kimovska Hristova, Vjekoslav Krzelj
Case Reports in Pediatrics.2025;[Epub] CrossRef
ПЕРВИННІ МІНОРНІ ІМУНОДЕФІЦИТИ ЯК ПРИЧИНА РОЗВИТКУ ІМУНОЗАЛЕЖНОЇ ПАТОЛОГІЇ У ЛЮДЕЙ: ЕТІОЛОГІЯ, ЕПІДЕМІОЛОГІЯ, КЛАСИФІКАЦІЯ, ДІАГНОСТИКА І ЛІКУВАННЯ (СИСТЕМАТИЧНИЙ ОГЛЯД)
Dmytro Maltsev
Immunology and Allergology: Science and Practice.2024; (3-4): 37. CrossRef

Original articles

Hematology
Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study: Jung Min Lee, Hee Jeong Cho, Joon-Ho Moon, Sang Kyun Sohn, Byunggeon Park, Dong Won Baek; J Yeungnam Med Sci. 2022;39(4):300-308. Published online March 23, 2022; DOI: https://doi.org/10.12701/jyms.2021.01648

7,187 View
89 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material

Background
This study investigated the prognostic impact of spine magnetic resonance imaging (MRI) in patients newly diagnosed with multiple myeloma (MM).
Methods
We retrospectively evaluated 214 patients who were newly diagnosed with MM between March 2015 and December 2019. The patients were classified into five different infiltration patterns based on spine MRI as follows: (1) normal appearance, (2) focal, (3) diffuse, (4) combined focal and diffuse infiltration, and (5) “salt-and-pepper.”
Results
Forty patients (18.7%) showed a normal appearance, whereas focal, diffuse, combined focal and diffuse infiltration, and “salt-and-pepper” patterns were identified in 68 (31.8%), 40 (18.7%), 52 (24.3%), and 14 patients (6.5%), respectively. The patients with normal and “salt-and-pepper” patterns were younger than patients with other patterns (median age, 61.6 vs. 66.8 years; p=0.001). Moreover, 63% and 59.3% of patients with normal and “salt-and-pepper” patterns were scored International Staging System (ISS) stage I and revised ISS (R-ISS) stage I, respectively, whereas only 12.5% of patients with other patterns were scored ISS stage I and R-ISS stage I. Patients with normal and “salt-and-pepper” patterns had a better prognosis than those with other patterns, whereas relapse and death rates were significantly higher in patients with focal, diffuse, and combined MRI patterns.
Conclusion
Characteristic MRI findings have a significant prognostic value for long-term survival in patients newly diagnosed with MM. In particular, focal, diffuse, and combined focal and diffuse infiltration patterns are unfavorable prognostic factors.

Citations

Citations to this article as recorded by

Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
Sung-Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang-Ki Min, Dok Hyun Yoon, Sung-Soo Yoon, Je-Jung Lee, Chae Moon Hong, Ka-Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok Do,
Blood Research.2025;[Epub] CrossRef
Lesions of the spinal cord caused by multiple myeloma: A systematic review and meta-analysis regarding the neurosurgical aspects of patient management
Daniel Encarnacion, Gennady E Chmutin, Ismail Bozkurt, Jack Wellington, Emmanuel Batista Geraldino, Bipin Chaurasia
Journal of Craniovertebral Junction and Spine.2023; 14(4): 313. CrossRef

Oncology and Cancer Research
Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study: Byung Woog Kang, Dong Won Baek, Eunhye Chang, Hye Jin Kim, Su Yeon Park, Jun Seok Park, Gyu Seog Choi, Jin Ho Baek, Jong Gwang Kim; J Yeungnam Med Sci. 2022;39(2):141-149. Published online December 22, 2021; DOI: https://doi.org/10.12701/yujm.2021.01571

9,145 View
111 Download
1 Web of Science
2 Crossref

Abstract PDF

Background
The present study evaluated the clinical implications of adjuvant chemotherapy according to the mismatch repair (MMR) status and clinicopathologic features of patients with intermediate- and high-risk stage II colon cancer (CC).
Methods
This study retrospectively reviewed 5,774 patients who were diagnosed with CC and underwent curative surgical resection at Kyungpook National University Chilgok Hospital. The patients were enrolled according to the following criteria: (1) pathologically diagnosed with primary CC; (2) stage II CC classified based on the 7th edition of the American Joint Committee on Cancer staging system; (3) intermediate- and high-risk features; and (4) available test results for MMR status. A total of 286 patients met these criteria and were included in the study.
Results
Among the 286 patients, 54 (18.9%) were identified as microsatellite instability-high (MSI-H) or deficient MMR (dMMR). Although all the patients identified as MSI-H/dMMR showed better survival outcomes, T4 tumors and adjuvant chemotherapy were identified as independent prognostic factors for survival. For the intermediate-risk patients identified as MSI-low (MSI-L)/microsatellite stable (MSS) or proficient MMR (pMMR), adjuvant chemotherapy exhibited a significantly better disease-free survival (DFS) but had no impact on overall survival (OS). Oxaliplatin-containing regimens showed no association with DFS or OS. Adjuvant chemotherapy was not associated with DFS in intermediate-risk patients identified as MSI-H/dMMR.
Conclusion
The current study found that the use of adjuvant chemotherapy was correlated with better DFS in MSI-L/MSS or pMMR intermediate-risk stage II CC patients.

Citations

Citations to this article as recorded by

Behavioral and Neuroanatomical Consequences of Cell-Type Specific Loss of Dopamine D2 Receptors in the Mouse Cerebral Cortex
Gloria S. Lee, Devon L. Graham, Brenda L. Noble, Taylor S. Trammell, Deirdre M. McCarthy, Lisa R. Anderson, Marcelo Rubinstein, Pradeep G. Bhide, Gregg D. Stanwood
Frontiers in Behavioral Neuroscience.2022;[Epub] CrossRef
A pilot retrospective study of comprehensive nursing care on psychological disorder in colorectal cancer undergoing chemotherapy
Zhou-Yi Zhang, Rui Wang, Li Zhang, Ming-Li Gu, Xiu-E Guan
Medicine.2022; 101(28): e29707. CrossRef

Case reports

Hematology
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report: Dong Won Baek, Yee Soo Chae; Yeungnam Univ J Med. 2021;38(4):366-370. Published online March 23, 2021; DOI: https://doi.org/10.12701/yujm.2021.00899

8,951 View
138 Download
7 Crossref

Abstract PDF

Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.

Citations

Citations to this article as recorded by

Immunotherapy-associated autoimmune hemolytic anemia induced by anti-PD-1 therapy in esophageal cancer: A case report and literature review
Zijian Qiu, Mixue Sun, Chunyan Dai, Xiaoping Zhu
Medicine.2025; 104(15): e42174. CrossRef
Severe immunotherapy-related autoimmune hemolytic anemia induced by toripalimab in a patient with deficient mismatch repair colorectal cancer: a case report and literature review
Xu Ma, Jin-Sheng Ye, Zhi Liu, Quan-Li Geng
Frontiers in Medicine.2025;[Epub] CrossRef
Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma
Hang-Yu Gu, Jing-Wen Zhao, Yin-Shuang Wang, Zhuo-Nan Meng, Xiu-Ming Zhu, Fu-Wei Wang, Ai-Hong Zheng, Guo-Qing Wu
Frontiers in Immunology.2023;[Epub] CrossRef
Immunotherapy-associated Autoimmune Hemolytic Anemia
Steven R. Hwang, Antoine N. Saliba, Alexandra P. Wolanskyj-Spinner
Hematology/Oncology Clinics of North America.2022; 36(2): 365. CrossRef
Therapeutic plasma exchange in the management of immune checkpoint inhibitor‐associated immune‐related adverse effects: A review
Oluwatoyosi A. Onwuemene, Chizoba I. Nnoruka, Christopher J. Patriquin, Laura S. Connelly‐Smith
Transfusion.2022; 62(11): 2370. CrossRef
Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer
Nabin Raj Karki, Peyton McElhone, Natasha Savage, Nagla Abdel Karim
BMJ Case Reports.2021; 14(8): e243751. CrossRef
Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors
Eungjun Yoon, Tae Yeul Kim, Sun Kyoung Mun, Duck Cho
The Korean Journal of Blood Transfusion.2021; 32(3): 201. CrossRef

Oncology and Cancer Research
Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance: Dong Won Baek, Ji-Young Park, Soo Jung Lee, Yee Soo Chae; Yeungnam Univ J Med. 2020;37(3):230-235. Published online January 22, 2020; DOI: https://doi.org/10.12701/yujm.2019.00423

11,289 View
164 Download
10 Crossref

Abstract PDF

Systemic therapy for metastatic triple-negative breast cancer (TNBC) still remains challenging because there are no targeted agents or endocrine therapies currently available. The present case report documents the successful use of cisplatin monotherapy to manage a heavily pretreated TNBC patient showing poor response to therapy. The patient was a 51-year-old woman who had already undergone several lines of systemic chemotherapy for widespread TNBC. Although the mutation analysis performed on DNA isolated from blood cells and progressed lesion samples confirmed the tumor to be germline BRCA wild-type, cisplatin monotherapy was administered based on the increasing evidence of safety and efficacy of platinum for breast cancer. After three cycles of cisplatin treatment, the patient’s metastatic lesions dramatically improved without any major toxicity, and she completed 17 cycles with good response. This case study indicates that patients with heavily pretreated TNBC can potentially achieve a good response to cisplatin monotherapy.

Citations

Citations to this article as recorded by

Mitochondrial Redox Vulnerabilities in Triple-Negative Breast Cancer: Integrative Perspectives and Emerging Therapeutic Strategies
Alfredo Cruz-Gregorio
Metabolites.2026; 16(1): 60. CrossRef
Synthesis, Structure, and Stability of Copper(II) Complexes Containing Imidazoline-Phthalazine Ligands with Potential Anticancer Activity
Łukasz Balewski, Iwona Inkielewicz-Stępniak, Maria Gdaniec, Katarzyna Turecka, Anna Hering, Anna Ordyszewska, Anita Kornicka
Pharmaceuticals.2025; 18(3): 375. CrossRef
Zeolitic Imidazole Framework/Silica Nanocomposite for Targeted Cancer Therapeutics: Comparative Study of Chemo-Drug Cisplatin (CPt) and Green Platinum (GPt) Efficacy
Hend Ghnaim Alotaibi, Eman Al-Abbad, Dana Almohazey, Vijaya Ravinayagam, Sultan Akhtar, Hatim Dafalla, B. Rabindran Jermy
International Journal of Molecular Sciences.2024; 25(6): 3157. CrossRef
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis
Mirosława Püsküllüoğlu, Małgorzata Pieniążek, Agnieszka Rudzińska, Agnieszka Pietruszka, Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Marek Ziobro
Oncology and Therapy.2024; 12(3): 419. CrossRef
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Nityanand Srivastava, Salman Sadullah Usmani, Rajasekaran Subbarayan, Rashmi Saini, Pranav Kumar Pandey
Frontiers in Oncology.2023;[Epub] CrossRef
Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway
Lu-Yao Zhang, Zhi-Xin Shen, Lu Guo
Cancer Investigation.2022; 40(4): 313. CrossRef
Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer
Reyhaneh Farghadani, Rakesh Naidu
International Journal of Molecular Sciences.2022; 23(4): 2144. CrossRef
Atorvastatin improves cisplatin sensitivity through modulation of cholesteryl ester homeostasis in breast cancer cells
Diandra Zipinotti dos Santos, Isabella dos Santos Guimaraes, Mariam F. Hakeem-Sanni, Blake J. Cochran, Kerry-Anne Rye, Thomas Grewal, Andrew J. Hoy, Leticia B. A. Rangel
Discover Oncology.2022;[Epub] CrossRef
Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
Andrew Sulaiman, Sarah McGarry, Jason Chambers, Emil Al-Kadi, Alexandra Phan, Li Li, Karan Mediratta, Jim Dimitroulakos, Christina Addison, Xuguang Li, Lisheng Wang
International Journal of Molecular Sciences.2020; 21(16): 5788. CrossRef
Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review
Jelena S. Katanic Stankovic, Dragica Selakovic, Vladimir Mihailovic, Gvozden Rosic
International Journal of Molecular Sciences.2020; 21(20): 7753. CrossRef

Original Article

Oncology and Cancer Research
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen: Hee-Jeong Cho, Sang-Kyung Seo, Dong Won Baek, Sung-Woo Park, Yoo-Jin Lee, Sang-Kyun Sohn, Ho-Sup Lee, Won Sik Lee, Ji Hyun Lee, Sung Hyun Kim, Joon-Ho Moon; Yeungnam Univ J Med. 2018;35(1):76-83. Published online June 30, 2018; DOI: https://doi.org/10.12701/yujm.2018.35.1.76

8,675 View
54 Download
4 Crossref

Abstract PDF

Background
Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ.
Methods
One-hundred and forty elderly patients who were diagnosed with MM from March 2007 to March 2015 were included in this retrospective study. To evaluate regimen adherence, patients who were treated with more than 4 cycles were assigned to the good adherence group.
Results
Among the 140 patients, 71 were treated with a frontline VMP and 69 with non-BTZ regimens. The median age was 71 years (range, 65-90 years). The VMP group showed a higher complete response rate than the non-BTZ group: 26.8% vs. 7.2%. More patients in the VMP group achieved ≥very good partial response (VGPR) and ≥PR. In the VMP group, 27 patients (38.0%) received less than 4 cycles. The VMP good adherence group showed a higher 3-year overall survival (OS) rate (70.9%) than the poor adherence group (60.2%, p=0.059). In the multivariate analysis, treatment with ≥4 cycles of VMP was a favorable factor for OS.
Conclusion
A good adherence to a frontline VMP regimen resulted in favorable long-term survival. Adequate management of AEs will be needed to achieve favorable outcomes in elderly patients with MM.

Citations

Citations to this article as recorded by

The characteristics of Korean elderly multiple myeloma patients aged 80 years or over
Sang Hwan Lee, Hee-Jeong Cho, Joon Ho Moon, Ji Yoon Jung, Min Kyoung Kim, Mi Hwa Heo, Young Rok Do, Yunhwi Hwang, Sung Hwa Bae
The Korean Journal of Internal Medicine.2025; 40(1): 115. CrossRef
Solomon Islands Oncology Unit: Sustainability in Terms of Outcomes
Dylan Bush, Mark Love, Hugo Bugoro, Nixon Panda
JCO Global Oncology.2024;[Epub] CrossRef
Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis
Abdallah Y. Naser, Richard Ofori-Asenso, Safaa Al Awawdeh, Sami Qadus, Hassan Alwafi, Danny Liew
Clinical Lymphoma Myeloma and Leukemia.2022; 22(10): 760. CrossRef
Oral therapy adherence and satisfaction in patients with multiple myeloma
Marine Solano, Etienne Daguindau, Cyril Faure, Pierre Loriod, Coline Pain, Anne-Cécile Maes, Pauline Marguet, Marie Kroemer, Anne Rumpler, Jean Fontan, Eric Deconinck, Samuel Limat, Anne-Laure Clairet
Annals of Hematology.2021; 100(7): 1803. CrossRef

First
Prev
Page of 1
Next
Last

Search